Small RNAs harboring regulatory function reflect the biology of developing tumor and immune system reactions and are prime targets of high-throughput expression profiling in whole-blood liquid biopsies.

Analyzing whole blood eliminates error-prone plasma processing at point of care, yet a large amount of uninformative data plagues the exploratory and financial potential of whole-blood analysis.

This webcast will describe how Hummingbird Diagnostics has addressed this dilemma with a pipeline for ultra-deep detection and validation of small RNAs. The pipeline has recently been used to uncover more accurate biomarkers for immunotherapy response prediction in advanced non-small cell lung cancer (NSCLC) patients.